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Abstract
Heterozygous loss-of-function mutation of the human gene for the mitochondrial protease HtrA2 has been associated
with increased risk to develop mitochondrial dysfunction, a process known to contribute to neurodegenerative disorders
such as Huntington’s disease (HD) and Parkinson’s disease (PD). Knockout of HtrA2 in mice also leads to mitochondrial
dysfunction and to phenotypes that resemble those found in neurodegenerative disorders and, ultimately, lead to death
of animals around postnatal day 30. Here, we show that Idebenone, a synthetic antioxidant of the coenzyme Q family,
and Resveratrol, a bioactive compound extracted from grapes, are both able to ameliorate this phenotype. Feeding
HtrA2 knockout mice with either compound extends lifespan and delays worsening of the motor phenotype.
Experiments conducted in cell culture and on brain tissue of mice revealed that each compound has a different
mechanism of action. While Idebenone acts by downregulating the integrated stress response, Resveratrol acts by
attenuating apoptosis at the level of Bax. These activities can account for the delay in neuronal degeneration in the
striata of these mice and illustrate the potential of these compounds as effective therapeutic approaches against
neurodegenerative disorders such as HD or PD.
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Introduction
Mitochondrial dysfunction has been implicated in the patho-
genesis of several neurodegenerative disorders such as Hunting-
ton’s disease (HD) and Parkinson’s disease (PD). These disorders
are characterized by the selective loss of neurons, accumulation of
reactive oxygen species (ROS), loss of mitochondrial membrane
potential, and ATP depletion [1], [2].
Administration of environmental toxins, like 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine or rotenone, in vivo is able to mimic
some pathological features of neurodegenerative disorders,
suggesting a cross-talk between mitochondrial dysfunction and
the ubiquitin proteasome system (UPS) [3].
HtrA2 (Omi) is a serine/threonine protease residing in the
intermembrane space of mitochondria attached to the inner
membrane. The absence of HtrA2 causes a parkinsonian
phenotype in knockout mice, which is characterized by an
accumulation of unfolded proteins inside mitochondria and [4]
defective mitochondrial respiration and enhanced ROS, either of
which can induce neuronal death through activation of the
internal stress response (ISR) by upregulation of the transcription
factor CHOP [5], [6]. Notwithstanding, the discussion remains on
whether HtrA2 is a susceptibility gene for neurodegenerative
disorders, although animal studies provide strong evidence for a
neuroprotective function for HtrA2 [7], [8], [5].
In line with this view, HtrA2 knockout (KO) mice exhibit
pronounced akinesia-like movement-related symptoms starting on
day 23 after birth. They show a focal loss of neurons with reactive
astrogliosis in the striatum and a selective loss of terminals in the
nigrostriatal pathway. At the time of death, which occurs on
average on post-natal day 28, neuronal degeneration is most
pronounced in the striatum but seems to progress, albeit at a
slower pace, in many areas of the brain including the forebrain
and (possibly) cerebellum [5].
To further validate the defect in oxidative stress resistance in
HtrA2 KO mice, we studied the effects of two compounds
(Idebenone and Resveratrol) on the disease course and on the
lifespan of HtrA2 KO animals and correlated these results with
expression levels of CHOP in different cell death models of
oxidative stress. In this regard, Idebenone is thought to have
antioxidant properties similar to CoQ10 which is in use for anti-
aging products on the basis of the free-radical theory [9].
Resveratrol (3,5,49-trihydroxystilbene) is both an antioxidant and
anti-inflammatory substance [10]. Interestingly, both Idebenone
and Resveratrol ameliorate disease symptoms in HtrA2 KO mice
while they show different effects on CHOP expression levels,
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pathways mediating pathology in neuronal disorders.
Materials and Methods
Ethics statement
All protocols are in accordance with the animal research
protocol 33.11.42502-04-117/08 of Niedersachsen and were
constantly supervised by veterinarians of the University Medical
Center, Goettingen.
Oral administration of Idebenone and Resveratrol
Since both drugs are known to pass the blood brain barrier after
oral administration, they were administered by mixing the drugs
with the regular feed of the animals [4], [11], [12,13].
A powder of feeding pellets was mixed with sugar and water. A
small portion of this sweet mash was prepared for each cage. The
animals prefer the sweetened food over the regular food and
usually completely ingested the portion of mash within minutes of
placing it into the cage. Idebenone or Resveratrol were suspended
in 0.5% methylcellulose (Sigma, Taufkirchern, Germany) and
mixed into the mash, at 500 mg/kg body weight for Idebenone
and as 25 mg/kg body weight for Resveratrol per day.
Concentrations of Idebenone and Resveratrol were chosen in
accordance to previous reports [14], [11]. Untreated controls
received the same amount of sweet mash without drugs. From
birth till weaning a single mother and her pups were housed in one
cage. Only the mother ate the mash, so the amount of drug was
adjusted to the body weight of the mother to yield the final
concentration. Both drugs can pass placenta, but the drug
concentration that pups received during this time was not
determined.
On post-natal day 5, pups received paw tattoos for identification
and KO mice were identified via PCR [6].
From post-natal day 20, mice were housed singly, and received
the sweet mash with or without drug adjusted for their body
weight. Animals were sacrificed when they were unable to walk.
Often, spontaneous death occurred before paralysis. In both cases,
day of death were noted. Mice used for longevity and motor task
experiments were sacrificed by carbon dioxide asphyxia.
For statistical analysis one-way ANOVA was carried out
followed by Mantel-Cox Test.
Motor task
Mice were placed into a modified inverted grid apparatus [15].
Mice were placed into the box with grid floor in the upright
position. Then the box was inverted and the time the mice could
cling to the grid floor was measured. The experiment was
conducted every other day, starting one day after weaning. Each
day consisted of 4 trials each, and the longest time the mouse could
cling to the grid was recorded. Maximum time per trial was one
minute. All mice, even untreated KO mice, were able to complete
at least one trial of one minute shortly after weaning. Successful
completion of the motor task was defined as the ability to hang
onto the grid for 10 sec or more.
Immunohistochemistry and stereology
For immunohistochemistry and molecular biological analysis,
six mice/treatment group were sacrificed using CO2. Brains were
rapidly removed, and dorsal striata from both hemispheres were
dissected on ice. One hemisphere of each brain was used for
mRNA analysis and the other hemisphere was fixed in 4%
paraformaldehyde for 48 hrs. After cryoprotection (30% sucrose),
30 mm coronal slices were cut in cryostat. For quantification of
neuron number in the striatum, free-floating, peroxidase based
immunohistochemistry was performed as we described previously
[16]. Briefly, every fifth sections was treated with anti-neuronal
nuclei (anti-NeuN) antibody (1:1000, Millipore, Billerica, MA,
USA) for 48 h at 4uC, then treated with biotinylated anti-mouse
IgG (1:200; Vector Laboratories, Burlingame, CA, USA) followed
by avidin–biotin–horseradish peroxidase (HRP) complex (1:500,
Vector Standard Elite Kit, Vector Laboratories, Burlingame, CA,
USA). Peroxidase labeling was visualized by diaminobenzidine
tetrahydrochloride. The omission of primary or secondary
antibodies resulted in a complete absence of immunoreactivity (ir).
The total number of NeuN-positive neurons in the dorsal
striatum [17] was counted (plate 21–31) by using the optical
fractionator, an unbiased stereological technique of cell counting
(StereoInvestigator, MBF Bioscience, Madgeburg) [18], [19].
Counts were performed blinded for experimental grouping, by
using an oil immersion 636 objective (Axioskop 2 microscope,
Zeiss, Jena, Germany), a counting frame of 50650 mm and a grid
size of 1006100 mm. Six slices/animal were used in the analysis,
and the size of the striatum was identical in wild-type and KO
animals.
The Two-way ANOVA followed by Newman–Keuls post hoc test
were carried out.
Realtime PCR analysis
cDNA was reverse transcribed from RNA extracted from cells
(cerebellar granule neurons) or from striatum derived from wt or
HtrA2 KO mice [5]. Real time PCR was performed by using
Mesa Blue qPCR MasterMix Plus for SYPR Assay low rox
(Eurogentec, Belgium). Primers for amplification of several genes
were designed by using the software Primer3 and are listed in
Table 1.
Statistical analysis
Data were analyzed using GraphPad Prism 4.0 (GraphPad
Software Inc.), using one-way ANOVA followed by Bonferroni’s
Multiple Comparison Test (real-time analysis), when significant
(p,0.05), unless otherwise noted. Statistical significance referred
to as: * p,0.05; ** p,0.01; *** p,0.001. All data are presented as
mean 6 SD.
For comparison of the curves in Fig.1a and b the Mantel-Cox
test was used.
In each curve, the smallest step down represents death (or
inability to complete the motor task) of one animal in the
respective treatment group, bigger steps represent events of
multiple animals on the same day.
Table 1. Primers used in this study.
Gene forward reverse
CHOP 59-CGGCCTGGGAAGCAACGCAT-39 59-GTCGATCAGAGCCCGCCGTG-39
ATF4 59-GGGTTCTGTCTTCCACTCCA-39 59-GGGCTCATACAGATGCCACT-39
p53 59-CACAGCGTGGTGGTACCTTA-39 59-TCTTCTGTACGGCGGTCTCT-39
Noxa 59-CGCGCAGAGCTACCACCTGA-39 5-TCCGGAGTTGAGCACACTCGT-39
Bcl2 59-TCGCAGAGATGTCCAGTCAG-39 59- ATGCCGGTTCAGGTACTCAG-39
Bax 59-ATGGAGCTGCAGAGGATCAT-39 59- GATCAGCTCGGGCACTTTAG-39
DR5 59GTCAGAAGGGAACTGCAAGC-39 59 -TGCATCGACACACCGTATTT-39
b-actin 59-GCGAGAAGATGACCCAGATC-3 59- CCAGTGGTACGGCCAGAGG-3
doi:10.1371/journal.pone.0028855.t001
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Longevity experiments, grid test and stereology
counting
To test whether the applied compounds were effective in vivo,
HtrA2 KO mice were fed with Idebenone or Resveratrol daily.
Both compounds increased life expectancy of HtrA2 KO mice
(n=77 (untreated), n=25 (Idebenone), n=34 (Resveratrol);
p=0.0013). Idebenone increased median survival by 7 days (from
32 to 39 days) and Resveratrol by 10 days (to 42 days) (Fig. 1a).
Both compounds significantly delayed onset and progression of
disease in HtrA2 KO mice, which usually develop first symptoms
consisting of neuromuscular abnormalities around post-natal day
23 leading to death around day 28 [5]. Disease progression was
systematically tested by an inverted grid test. Both compounds
significantly extend the period of life during which the animals
were able to successfully perform the motor task. (Fig. 1b) (n=5
(untreated), n=10 (Idebenone), n=6 (Resveratrol). Untreated
animals had a median lifetime of 27 days during which they were
able to perform the task. Resveratrol increased this period by 5.5
days to 32.5 days (p=0.003) and Idebenone increased it by 8.5
days to 35.5 days (p=0.0001). Both compounds also substantially
increased maximal lifetime by which individuals could perform the
task. Untreated animals were able to hang onto the grid for at least
30 seconds up to an age of at most 29 days, whereas in the treated
groups 10%, respectively 17% of the animals could perform up to
an age of at least 48 days for Resveratrol and Idebenone. The
maximum lifetime during which the task could be completed was
66 days for Resveratrol and 63 days for Idebenone.
Using a grip strength meter, we attempted to analyze whether
the failure to complete the motor task was due to lack of motor
strength or loss of coordination (data not shown). However, it was
unclear whether the mice released the grip because of lack of
coordination or motor strength or both. We could therefore not
clearly test whether the KO lead to loss of coordination or
strength, or both; similarly we cannot conclude which one of these
attributes was improved by Idebenone and Resveratrol.
In order to test if this attenuation of phenotype by Idebenone
and Resveratrol is reflected by decreased degeneration of striatal
neurons, which had been described as a pathological hallmark in
HtrA2 KO mice [5], we examined brains of treated and untreated
wt and KO animals sacrificed on post-natal day 30. Lack of the
HtrA2 protein resulted in a loss of neurons in the dorsal part of the
striatum (p=0.0001; Fig. 2). Daily supply with either Resveratrol
or Idebenone indeed revealed a small but significant increase in
neuronal density (p=0.009 for Idebenone and p=0.0013 for
Resveratrol) when compared to untreated KO animals (Fig. 2).
The absolute size of the striatum was constant in all treatment
groups. Therefore, these data indicate a rescue effect of total
neuron numbers by both compounds.
CHOP expression in the striatum from HtrA2-KO animals
treated with Idebenone and Resveratrol
To test whether neurodegeneration involves the same pathways
described previously [6], we analyzed CHOP mRNA levels in
brain tissue taken from striatum of the brain derived from HtrA2
KO mice on day 30 after birth, since this brain area is primarily
affected histopathologically [5]. HtrA2 KO mice showed strongly
elevated CHOP levels measured in the striatum in comparison to
Figure 1. Treatment of HtrA2 KO animals with Idebenone and
Reseveratrol. A Both Idebenone (orange line, 25 animals) and
Reseveratrol (green line, 34 animals) significantly increased the mean
survival time of HtrA2 KO mice compared to sham-treated animals
(black line, 77 animals,). In addition, Idebenone increased the maximal
life span. B Grid test of HtrA2 KO animals. Both compounds extend the
period of life during which the KO animals can perform the motor task
successfully (Idebenone: 10 animals, resveratrol: 6 animals, untreated 5
animals).
doi:10.1371/journal.pone.0028855.g001
Figure 2. Quantification of neuronal density in dorsal part of
striatum. A NeuN staining in the dorsal part of the striatum. Scale bar:
280 mm. B The treatment with Idebenone and Reseveratrol could
significantly attenuate neuronal loss in the dorsal part of the striatum of
KO mice. Six mice/treatment group were analyzed.
doi:10.1371/journal.pone.0028855.g002
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reduced by Idebenone in this brain area to roughly 50% of
untreated KO mice. Resveratrol caused a lesser, not significant
reduction in levels of CHOP-mRNA (Fig. 3a). Treatment of
cerebellar granule neurons of HtrA2 KO mice (see SI Methods)
with idebenone prevented the increase of CHOP-mRNA in vitro
(Fig. S1).
Examination of signaling cascades involving CHOP in
HtrA2 KO mice
Existing data show that induction of CHOP is mainly linked to
ER stress inducing the Unfolded Protein Response (UPR) [20] via
the up-regulation of transcription factor ATF4, but it was also
described as being part of the ISR [21], [6].
Relative expression of the transcription factor ATF4, the
possible activator of CHOP, was increased in the striatum of
HtrA2 KO mice, whereas treatment with Idebenone or Resver-
atrol had no effect on its expression (Fig. 3b).
To further address if HtrA2 KO mice displayed different
expression patterns of mRNAs linked to the Bcl2-family, we
analyzed material from the striatum and focused on pro- and anti-
apoptotic members, e.g. Bax and Bcl2.
HtrA2 KO animals showed no down-regulation for mRNAs of
the anti-apoptotic Bcl2 gene (Fig. 3c), whereas up-regulation of the
pro-apoptotic factor Bax occurred in the striatum (Fig. 3d). Life
extension therapy with Resveratrol could decrease the elevated
expression of Bax, whereas treatment with Idebenone showed
non-significant effect (Fig. 3d).
As shown in Fig. 3e, elevated striatal levels of another pro-
apoptotic member of Bcl2-family, Noxa, in HtrA2 KO mice
declined to wt levels under Idebenone treatment while Resveratrol
had no effect. Initial observations indicated that Noxa mRNA is
primarily a p53-response gene. To clarify whether up-regulation of
Noxa in the brain was dependent on p53, we performed analysis of
p53 transcript levels of different brain areas derived from HtrA2
KO animals. Neither Idebenone nor Resveratrol treatment
changed the elevated p53 expression levels in the striatum of
HtrA2 KO mice significantly (Fig. 3f).
Since CHOP is known to regulate Death Receptor 5 (DR5)
expression via binding to its promoter region [22], [23], [24], we
next examined if the lack of HtrA2 mediates the activation of DR5
in the striatum of HtrA2 KO mice. This was indeed the case.
Treatment with Idebenone reduced elevated expression levels of
DR5 in the striatum down to wt levels while Resveratrol had no
reducing effect (Fig. 3g).
Discussion
Despite the controversy on whether HtrA2 might constitute a
susceptibility to PD, HtrA2 knockout mice suffer from loss of a
certain neuronal populations in the striatum, which resembles a
neurodegenerative disorder with a parkinsonian phenotype. Loss
of function analysis showed, that HtrA2 has important function in
the maintenance of mitochondrial integrity, because absence of
the protein leads to accumulation of unfolded proteins in the
mitochondria, leading to increased levels of the transcription factor
CHOP and cell death, supporting the importance of HtrA2 in the
cellular quality control of proteins in neurodegenerative processes
[5], [6].
Moreover HtrA2 is sought to regulate constitutive autophagy,
which represents an alternative cell death pathway. Therefore
HtrA2 induced autophagy by digestion of Hax1 (member of the
Bcl2-family), which binds to Beclin-1 (initiator of autophagy) [25].
However, we could not detect differences in the Hax1-expression
in wt and HtrA2 KO mice (data not shown).
In the present study we show that Idebenone and Resveratrol
have beneficial effects in HtrA2 KO mice in vivo and in vitro.
Since HtrA2 KO mice are not fertile, progeny have to be bred
from heterozygous parents. Therefore only 25% of progeny are
HtrA2 KO animals. For in vitro experiments we needed to test both
compounds in neuronal cell cultures and therefore we resorted to a
model of primary neuronal culture that can be prepared from
postnatal progeny allowing enough time for genotyping and
identification of KO individuals.
Although cerebellar granule neurons are not primarily affected
in the brain of HtrA2 KO mice, we provide clear evidence for
neurodegeneration in these neurons as indicated by increased
CHOP levels [6].
Untreated cultures derived from HtrA2 KO animals showed
approximately five fold elevated CHOP levels compared to their
wt counterparts. Neither Idebenone nor Resveratrol affected
CHOP levels in wt cells, but in HtrA2 KO cultures Idebenone
could reduce the amount of CHOP-mRNA to wt levels.
Resveratrol had no effect on CHOP expression (Fig. S1; [41]).
Our experiments show also that although Idebenone and
Resveratrol act via distinct pathways, both treatments reduce
activation of pro-apoptotic factors. In addition, we were able to
identify different signaling steps activated by Idebenone and
Resveratrol. A possible model for the molecular way of action of
our test compounds is presented in Fig. 4.
HtrA2 appears to be crucial for the maintenance of normal
mitochondrial function. Absence of HtrA2 induces disease
progression characterized by elevated oxidative stress, followed
by up-regulation of the transcription factor CHOP via the
activation of ISR and finally apoptosis [6].
Interestingly, both tested compounds extended lifespan, delayed
disease onset and increased neuronal density in the striata of
treated HtrA2 KO mice. However, Idebenone reduced CHOP
expression in vitro and in vivo, whereas Resveratrol did not. To
explain these controversial results, we analyzed the expression of
genes from different molecular pathways. There are two major
apoptotic signaling pathways: the intrinsic, mitochondria-mediat-
ed pathway linked to members of the Bcl2-familiy and the
extrinsic, death receptor-induced pathway [26]; [27]. CHOP is
part of the intrinsic apoptotic pathway and can be activated by the
upstream transcription factor ATF4 [28]. Up-regulation of ATF4
represents one upstream element of CHOP activation, and
therefore a receptive step in the ISR for life-extending therapy
with Idebenone or Resveratrol. Idebenone clearly reduced CHOP
levels, but did not influence the levels of expression of the
upstream activator ATF4. Idebenone is an orally bioavailable Q10
derivative [9], used for the treatment of Friedreich’s ataxia [29].
The strong anti-oxidant properties of Idebenone could explain
why treatment promotes down-regulation of the oxidative stress
factor CHOP.
Activation of CHOP leads also to up-regulation of diverse
downstream targets, which are not yet fully defined, but largely
known as initiators of apoptosis. In this regard, CHOP is believed to
shift mRNA expression levels of Bcl2-family proteins towards pro-
apoptotic members, e.g. Bax [21]. Interestingly, HtrA2 KO animals
showed no reduced levels of Bcl2, but elevated levels of Bax when
compared to wt animals. Treatment of HtrA2 KO with Idebenone
or with Resveratrol had no significant effect on Bcl2-expression.
However, we observed a substantial down-regulation of Bax
expression after Resveratrol treatment, an effect that might be
independent fromCHOP.Itis more likelythat Baxcanbeactivated
by other pro-apoptotic factors, linked to the intrinsic and/or
Treatment against Neurodegeneration in Omi KO Mice
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Noxa, which can neutralize the pro-survival Bcl2-family protein
Mcl1/Al, thereby facilitating activation of Bax/Bak proteins.
Interestingly, expression of Noxa was suppressed by Idebenone
treatment, while the upstream activator of Noxa, p53 [30], was not
affected. Although Idebenone and Resveratrol extended lifespan of
HtrA2 KO mice, these compounds did not alter the expression of
the upstream elements ATF4 and p53 within the activation cascade
of Bax. However, we cannot rule out the possibility that Idebenone
and Resveratrol might regulate these transcription factors at
translational or post-translational levels.
The intrinsic apoptotic pathway might be linked to the extrinsic
pathway, for example through activation of caspase-8 or the
bifunctional apoptosis regulator protein BAR [31], leading to an
increased expression profile of pro-apoptotic members of the Bcl2-
family, e.g. BID and Bax/Bak proteins. This amplifying effect
triggers the damage of mitochondria, leading to caspase activation
downstream of mitochondria [32]. Thus, we examined Death
Receptor 5 (DR5), which belongs to the to the Tumor Necrosis
Factor Receptor (TNFR) superfamily and is uniquely character-
ized by the presence of a ‘‘death domain‘‘ motif in their
cytoplasmic C-terminal region that is crucial for transmitting
apoptotic or other signals [33]. Indeed, HtrA2 KO animals
showed elevated levels of DR5 mRNA in the striatum, and
Idebenone reduced its expression.
Since we did not observe modulation of Bax levels under
Idebenone treatment, the regulation of Noxa and DR5 probably
alters mitochondrial translocation and oligomerization of Bax
[34]; [32], thereby inhibiting apoptosis in HtrA2 KO mice. In
contrast, Resveratrol reduced Bax expression, but failed to
decrease the expression of other tested genes indicating that these
compounds act differentially at the molecular levels.
Resveratrol has been shown to be neuroprotective in in vivo and
in vitro models of PD [35]; [36]. Resveratrol is orally bioavailable
but metabolized quickly [37]. However, the effective metabolite is
still not known. Resveratrol is one of the active ingredients in
grape extract that extended lifespan and improved motor function
in a drosophila model of PD due to its antioxidant effect [38]. One
of its best studied cell biological targets is the activation of sirtuin 1,
a protein involved in aging [39]; [40].
Overall, our results support the feasibility of potential treatment
of neurodegenerative diseases like PD with the agents studied here,
especially since standard treatment strategies are essentially
symptomatic. Since both compounds are known to be well
tolerated [29]; [37] and have been administered in patients
already, we propose human trials with Resveratrol and Idebenone
especially in patients carrying the HtrA2/Omi mutation.
In summary, our data suggests that Idebenone acts upstream on
the expression levels of CHOP but downstream of ATF4, and
upstream of Noxa but downstream of p53 in the intrinsic apoptotic
pathway (Fig. 4). Regarding the extrinsic pathway Idebenone
appears to exert pro-survival effects on DR5 expression via CHOP
down-regulation. Conversely, Resveratrol seems to act only as Bax
regulator in this context. In any case, both reagents induce a
decreased activation of pro-apoptotic factors and thereby extend
the survival rate of HtrA2 KO mice.
Supporting Information
Figure S1
(TIF)
Figure 3. Relative expression of different genes involved in the pathogenesis of HtrA2 KO. A Relative expression of CHOP in the striatum.
HtrA2 KO animals showed elevated levels of CHOP levels compared to wt. After treatment with Idebenone HtrA2 KO animals showed reduced levels
of CHOP. B Relative expression of ATF4 in the striatum. Levels of ATF4 were elevated in HtrA2 KO mice compared to wt, but not influenced by
Idebenone or Reseveratrol treatment. C Relative expression of Bcl2 in the striatum. The relative expression of Bcl2 was not up-regulated in HtrA2 KO
animals. Neither treatment with Idebenone nor with Reseveratrol changed the relative expression of Bcl2. D Relative expression of Bax in the striatum.
HtrA2 KO animals exhibited elevated expression levels of Bax. Treatment with Reseveratrol attenuated the up-regulation of Bax. E Relative expression
of Noxa in the striatum. HtrA2 KO animals showed increased relative expression of Noxa. Treatment with Idebenone of HtrA2 KO animals induced
down-regulation of Noxa. F Relative expression of p53 in the striatum. HtrA2 KO animals showed upregulated expression levels of p53, while
treatment with Idebenone and Reseveratrol had no effect on this. G Relative expression of DR5 in the striatum. The elevated levels of DR5 could be
reduced after treatment with Idebenone. Empty bars: wt, grey bars: HtrA2 KO. Data are mean6 SD; *** p,0.001, ** p,0.01, * p,0.05, ns: not
significant; n=6 mice/group.
doi:10.1371/journal.pone.0028855.g003
Figure 4. Signaling cascades involving CHOP in the striatum of
HtrA2 KO mice. The existence of HtrA2 appears to be crucial for
disease progression characterized by mitochondrial dysfunction, which
contributes to neuronal cell death via up-regulation of the transcription
factors ATF4 and CHOP. CHOP is known to repress Bcl2 (pro-survival)
gene expression, which increases the proportion of pro-apoptotic Bcl2
proteins such as Bax. Oxidative stress also leads to an up-regulation of
the pro-apoptotic Bcl2- protein Noxa, which can be activated by the
transcription factor p53. Noxa exerts its pro-apoptotic function by
neutralizing the pro-survival Bcl2 protein Mcl1/Al, thereby facilitating
the activation of Bax/Bak proteins. CHOP is also known to regulate the
extrinstic apoptotic signaling pathway by activating Death Receptor 5
(DR5), a member of the TNFR superfamily, by binding to its promoter
region. Idebenone excerts anti-apoptotic effects on CHOP- and Noxa
activation downstream of ATF4 and p53, respectively. Idebenone
induces also anti-apoptotic effects on DR5 expression. Reseveratrol has
been shown to reduce the expression of Bax, downstream of the CHOP-
and Noxa activation cascades. Pro-apoptotic factors placed in grey
boxes and anti-apoptotic factors placed in white boxes. Antioxidant
compounds, used in this study, placed in white boxes with double lines,
dashed lines stay for dependent interactions known from literature,
solid lines represent dependent interactions drawing from experimental
data shown her.
doi:10.1371/journal.pone.0028855.g004
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